Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs | Zendy

Ziqin Cao | Zendy; Jian Zhou | Zendy; Zeling Long | Zendy; Yihan Li | Zendy; Jingjing Sun | Zendy; Yingquan Luo | Zendy; Wanchun Wang | Zendy

Open Access

Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs

Author(s) -

Ziqin Cao,

Jian Zhou,

Zeling Long,

Yihan Li,

Jingjing Sun,

Yingquan Luo,

Wanchun Wang

Publication year - 2020

Publication title -

aging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.473

H-Index - 90

ISSN - 1945-4589

DOI - 10.18632/aging.202232

Subject(s) - medicine , osteoarthritis , placebo , nausea , cochrane library , nerve growth factor , meta analysis , adverse effect , pathology , alternative medicine , receptor

Osteoarthritis (OA) is the most common joint disease and leading cause of pain and disability in the elderly population. Most guidelines recommend the use of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids for the non-operative treatment of OA. Monoclonal nerve growth factor (NGF) antibodies are new drugs with the potential to provide pain relief and functional improvement in OA. We compared the efficacy (pain reduction and functional improvement), and safety of monoclonal NGF antibodies with NSAIDs and opioids in the treatment of OA with a Bayesian network meta-analysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research